Article info

Download PDFPDF

Extended report
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Authors

  1. Correspondence to Dr Stevan Shaw, New Medicines, UCB Pharma, Slough SL1 3WE, UK; stevan.shaw{at}ucb.com
View Full Text

Citation

Glatt S, Baeten D, Baker T, et al
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Publication history

  • Received July 26, 2017
  • Revised October 27, 2017
  • Accepted November 19, 2017
  • First published December 23, 2017.
Online issue publication 
March 12, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.